Recognizing Renal Medullary Carcinoma: Red Flags for Community OncologistsByPavlos Msaouel, MD, PhDApril 1st 2026
CD19 CAR T Efficacy Is Consistent Across Race in B-Cell LymphomasByAndrea Eleazar, MHSMarch 31st 2026
FDA Grants Lirafugratinib Priority Review in FGFR2-Altered CholangiocarcinomaByErin DoranMarch 30th 2026